Memphasys Secures 100 Monthly Felix™ Cartridge Orders from Hamad Medical Corporation
Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.
- Hamad Medical Corporation initiates commercial use of Felix™ cartridges
- Initial demand at ~100 cartridges per month supporting 1,500 IVF cycles annually
- Additional 200 cartridges ordered via distributor ITL reflecting wider MENA interest
- CE Mark approval enables immediate clinical deployment in Qatar and other markets
- Ongoing late-stage contract talks across five other MENA countries
Institutional Adoption Signals Regional Breakthrough
Memphasys Limited (ASX – MEM) has announced a major commercial milestone with Qatar’s largest fertility institution, Hamad Medical Corporation (HMC), commencing clinical use of its patented Felix™ system. This development marks a significant step in Memphasys’ strategic rollout across the Middle East and North Africa (MENA) region, validating the system’s clinical value and commercial appeal.
HMC, a leading public health provider conducting approximately 1,500 assisted reproductive technology (ART) cycles annually, has begun ordering Felix™ cartridges at an initial rate of around 100 per month. This volume not only supports a substantial number of IVF procedures but also establishes a recurring revenue stream that underpins Memphasys’ regional commercial ambitions.
Broader Regional Demand and Distribution Momentum
Beyond Qatar, Memphasys has secured a follow-on order for 200 additional Felix™ cartridges through its distribution partner International Technical Legacy (ITL). This order reflects growing procurement activity across the MENA clinic network, including the United Arab Emirates, and signals increasing confidence in Felix™ technology among IVF operators.
With over 350 clinics in the MENA region, each with the potential to generate significant cartridge revenue, the market opportunity for Memphasys is substantial. The company is also engaged in late-stage contractual discussions with clinics in five other countries, indicating accelerating adoption and a promising pipeline of future sales.
Regulatory Approval and Strategic Engagement
The CE Mark approval for Felix™ facilitates immediate clinical use in Qatar and other CE-recognised MENA markets, removing a key barrier to market entry. This regulatory milestone has been instrumental in driving uptake and enabling Memphasys to execute its go-direct commercial strategy effectively.
Supporting this momentum, Associate Professor Hassan Bakos, Director of Clinical Partnerships and Growth, has undertaken multiple visits to the region to optimise utilisation at HMC, onboard additional clinics, and engage with clinicians at major ART conferences, particularly in Egypt, a priority expansion market with a rapidly growing IVF sector.
Outlook – A New Phase of Commercial Execution
Memphasys’ Chair of the Commercialisation Committee, Marjan Mikel, emphasised that the combination of institutional adoption at HMC and broader regional demand through ITL underscores the effectiveness of their commercial approach. As Felix™ gains traction, the company is poised to capitalize on the expanding MENA market, which offers a scalable and lucrative opportunity for growth.
While the initial orders and engagements are promising, the company’s ability to convert late-stage discussions into firm contracts will be critical in sustaining this momentum and delivering on its growth potential.
Bottom Line?
Memphasys is entering a pivotal growth phase in MENA, with institutional validation setting the stage for wider regional adoption.
Questions in the middle?
- How quickly will Memphasys convert late-stage discussions into binding contracts across the MENA region?
- What impact will increased Felix™ adoption have on Memphasys’ revenue and margin profiles in the near term?
- How will competitive dynamics in the MENA IVF market influence Memphasys’ commercial strategy and pricing?
